Nuvation Bio Inc. Deferred Tax Assets, Operating Loss Carryforwards
Nuvation Bio Inc. (NUVB) had Deferred Tax Assets, Operating Loss Carryforwards of $127.34 million as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-02
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $127.34M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $107.70M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $29.29M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $22.18M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $127.34M 10-K · filed 2026-03-02 | |
| 2024-12-31 | $107.70M 10-K · filed 2026-03-02 | |
| 2023-12-31 | $29.29M 10-K · filed 2025-03-06 | |
| 2022-12-31 | $22.18M 10-K · filed 2024-02-29 | |
| 2021-12-31 | $13.44M 10-K · filed 2023-03-15 | |
| 2020-12-31 | $4.43M 10-K · filed 2022-02-28 | $28.20K 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |